undamentalytics Newsletter
Sign in

Phreesia, Inc. (PHR) stock

Add to watchlist

Add holding +

NYSE: PHR NYSE Health Care Technology Next results ~December 7, 2026

C+ Fundamentals grade

Phreesia, Inc. is a US-listed company in the health care technology industry. Its financial year ends in January.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$12

Valuation models combined (4)

Base case. Range ~$5.3–$21. Weighted average of 4 models (growth cash-flow model, forward price-to-earnings vs peers, forward price-to-sales vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Phreesia, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Phreesia files

Where Phreesia stands after its latest 10-Q

Revenue for the twelve months to July 2026 was $508m, up 12.9% on a year earlier, slower than the 14.1% growth a quarter earlier. Free-cash-flow margin rose to 15.9% from 9.6% a year earlier. Operating margin widened to 2.5% from -5.8%. The diluted share count is up 5.5% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 6 of our 7 financial-health checks.

Source: 10-Q filed September 3, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~December 7, 2026 (estimated)

Phreesia, Inc.'s trailing-twelve-month revenue grew 12.9% year on year, with a free-cash-flow margin of 15.9%. Where it stands out: long-term debt as % of assets of 0.2% ranks 2 of 15 health care technology companies we cover.

Current signal Balance sheet growing far ahead of sales: Total assets grew 58% year over year while revenue grew 13% — the balance sheet is expanding 45 points faster than the business it supports.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 8.3 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Share dilution. Diluted shares rose 5.5% in a year.
  • High earnings multiple. The shares trade at 74 times the last 12 months' earnings, so expectations are demanding.
  • Volatile shares. Over the past year the shares showed annualised volatility of 58% and a beta of 0.2 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results: FY2027 Q2

Filed September 3, 2026
Earnings per share
$0.28 against an average estimate of $0.32: missed by 14.3%
Revenue
$129m, up 10.4% on a year earlier
Share reaction
-6.2% in the first session after the results on September 2, 2026, against +1.5% for the S&P 500
Next report
September 2, 2026; average EPS estimate $0.36

Phreesia's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day0.0%
  • 1 week-1.3%
  • 1 month+23.5%
  • This year-26.5%
  • 1 year-45.1%
  • 5 years-83.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$508M
Operating margin
2.5%
Net margin
2.1%
EPS (TTM, diluted)
$0.17

Growth

Revenue growth
+12.9%
Change in growth rate
−1.1 pts
Share count change
+5.5%

Cash

Free cash flow (TTM)
$80.7M
FCF margin
15.9%
Stock pay % of revenue
11.7%

Earnings

Last results
September 2, 2026
Next results (est.)
December 7, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Phreesia, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Phreesia, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.14 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$5.3 ~$3.5–$6.1 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$21 ~$16–$34 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$12 ~$9.9–$40 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$18 ~$14–$22 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$12 ~$5.3–$21 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Phreesia, Inc. with Health Care Technology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2020202120222023202420252026Now
Share price$31.00$65.29$31.19$37.49$25.48$28.46$13.43$12.44
Market value$1.3bn$2.6bn$1.6bn$2.0bn$1.4bn$1.6bn$826m$777m
+ Net debt (− = net cash)−$90m−$219m−$314m−$177m−$88m−$84m−$74m$53m
Enterprise value$1.2bn$2.4bn$1.2bn$1.8bn$1.3bn$1.6bn$752m$830m
Multiples
Price / sales 10.1x17.4x7.3x7.0x3.9x3.9x1.7x1.5x
Price / earnings ——————n/m74.4x
Price / free cash flow —————69.2x12.2x9.6x
EV / EBITDA ——————30.3x16.7x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

11 /100

Weak moat

How hard Phreesia's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -13.0% of total assets over 8 years.

  • Durability 10 / 20

    Operating margin has been a median -19.4%; its worst year was -73.1%.

  • Cash conversion 3 / 20

    Free cash flow was positive in 2 of 8 years, at a median -6.7% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 39.6% over five years; stock-based pay has been a median 13.3% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (16 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $1.27 −2% $516m +7%
Next $1.60 +26% $535m +4%

Next year's EPS estimate has moved −0.5% in 90 days, across 9 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −4.7% on 90 days ago. In the last 30 days, 0 analysts raised Phreesia, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Phreesia, Inc., last 90 days
$1.20 $1.30 $1.40 $1.50 $1.60 $1.70 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $1.33 Current fiscal year, 60 days ago: $1.33 Current fiscal year, 30 days ago: $1.24 Current fiscal year, 7 days ago: $1.28 Current fiscal year, Now: $1.27 $1.27 Next fiscal year, 90 days ago: $1.61 Next fiscal year, 60 days ago: $1.61 Next fiscal year, 30 days ago: $1.61 Next fiscal year, 7 days ago: $1.61 Next fiscal year, Now: $1.60 $1.60

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $1.33$1.61
60 days ago $1.33$1.61
30 days ago $1.24$1.61
7 days ago $1.28$1.61
Now $1.27$1.60

Earnings against estimates

Quarter toEstimateActualSurprise
Jul 2026 $0.32 $0.28 −14.3%
Apr 2026 $0.29 $0.27 −6.4%
Jan 2026 $0.32 $0.44 +38.0%
Oct 2025 $0.24 $0.31 +27.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

18 analysts, Oct 2026
Buy1056%
Hold844%
Sell00%

Monthly trend

  1. Oct 202628818
  2. Sep 202628818
  3. Aug 202638819
  4. Jul 202638819

Counts of recommendations published by analysts covering Phreesia, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.1%
of tradable shares
Days to cover
4.49
at average volume
Short interest, 1 month
−1%
to October 15, 2026
Held by institutions
96%
of shares
Held by insiders
6.3%
of shares
Employees
1,789
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −45.1%

$22.64 on October 31, 2025 to $12.44

ThenNowEffect
Revenue (last 12 months) $450m $508m +12.9%
P/S multiple 3.0x 1.5x −48.7%
Share count 59m 62m −5.2%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −23.9%

$16.35 on November 3, 2023 to $12.44

ThenNowEffect
Revenue (last 12 months) $319m $508m +59.0%
P/S multiple 2.7x 1.5x −43.8%
Share count 53m 62m −14.9%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PHR−23%−22%−29%+9%−33%−27%
Industry peers (median)−9%−67%−16%−24%−27%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PHR42%42%42%50%25%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PHR−51%−68%−69%−38%−53%−54%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since July 18, 2019: 90% from February 9, 2021 to April 10, 2026. Getting back needed a 900% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$8.06 – $23.15
From 52-week high
−46.3%
vs 50-day average
+12.6%
vs 200-day average
+14.1%
Volatility (1 year)
58%
Beta vs S&P 500
0.20

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±10.2%
After a week
5 up, 7 down
typical move ±11.1%
After a month
5 up, 7 down
typical move ±12.8%
Results releasedNext dayS&P 500 next day5 days21 days
September 2, 2026 −6.2% +1.5% −14.1% −14.9%
May 27, 2026 +5.6% +0.5% +7.8% +12.5%
April 3, 2026 +9.3% +0.5% −3.7% +15.5%
March 30, 2026 −23.7% +2.6% −17.5% −14.7%
December 8, 2025 −24.0% −0.4% −17.7% −16.7%
September 4, 2025 −7.6% +0.5% −16.3% −23.6%
May 28, 2025 −2.1% −0.2% +1.1% +14.2%
March 12, 2025 +9.6% −0.8% +24.8% +3.3%
December 9, 2024 +11.1% −0.8% +18.0% +22.8%
September 4, 2024 +7.9% −0.4% −2.0% −7.3%
May 30, 2024 −13.3% +0.2% −9.5% −5.3%
March 14, 2024 +1.7% −0.9% +1.0% −2.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Phreesia, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Phreesia, Inc.
$300M $350M $400M $450M $500M $550M FY24 Q3 FY25 Q2 FY26 Q1 FY27 Q2 Revenue (TTM), FY24 Q3: $337.9M Revenue (TTM), FY24 Q4: $356.3M Revenue (TTM), FY25 Q1: $373.7M Revenue (TTM), FY25 Q2: $390M Revenue (TTM), FY25 Q3: $405.1M Revenue (TTM), FY25 Q4: $419.8M Revenue (TTM), FY26 Q1: $434.5M Revenue (TTM), FY26 Q2: $449.7M Revenue (TTM), FY26 Q3: $463.2M Revenue (TTM), FY26 Q4: $480.6M Revenue (TTM), FY27 Q1: $495.6M Revenue (TTM), FY27 Q2: $507.8M $507.8M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q3 $337.9M
FY24 Q4 $356.3M
FY25 Q1 $373.7M
FY25 Q2 $390M
FY25 Q3 $405.1M
FY25 Q4 $419.8M
FY26 Q1 $434.5M
FY26 Q2 $449.7M
FY26 Q3 $463.2M
FY26 Q4 $480.6M
FY27 Q1 $495.6M
FY27 Q2 $507.8M
Revenue growth, TTM YoY Phreesia, Inc.
10% 15% 20% 25% 30% FY24 Q3 FY25 Q2 FY26 Q1 FY27 Q2 Revenue growth, TTM YoY, FY24 Q3: 28.8% Revenue growth, TTM YoY, FY24 Q4: 26.8% Revenue growth, TTM YoY, FY25 Q1: 24.0% Revenue growth, TTM YoY, FY25 Q2: 22.1% Revenue growth, TTM YoY, FY25 Q3: 19.9% Revenue growth, TTM YoY, FY25 Q4: 17.8% Revenue growth, TTM YoY, FY26 Q1: 16.3% Revenue growth, TTM YoY, FY26 Q2: 15.3% Revenue growth, TTM YoY, FY26 Q3: 14.3% Revenue growth, TTM YoY, FY26 Q4: 14.5% Revenue growth, TTM YoY, FY27 Q1: 14.1% Revenue growth, TTM YoY, FY27 Q2: 12.9% 12.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q3 28.8%
FY24 Q4 26.8%
FY25 Q1 24.0%
FY25 Q2 22.1%
FY25 Q3 19.9%
FY25 Q4 17.8%
FY26 Q1 16.3%
FY26 Q2 15.3%
FY26 Q3 14.3%
FY26 Q4 14.5%
FY27 Q1 14.1%
FY27 Q2 12.9%
Operating margin (TTM) Phreesia, Inc.
-60% -40% -20% 0% 20% FY24 Q3 FY25 Q2 FY26 Q1 FY27 Q2 Operating margin (TTM), FY24 Q3: -43.4% Operating margin (TTM), FY24 Q4: -38.3% Operating margin (TTM), FY25 Q1: -31.6% Operating margin (TTM), FY25 Q2: -25.2% Operating margin (TTM), FY25 Q3: -19.8% Operating margin (TTM), FY25 Q4: -13.8% Operating margin (TTM), FY26 Q1: -9.7% Operating margin (TTM), FY26 Q2: -5.8% Operating margin (TTM), FY26 Q3: -1.9% Operating margin (TTM), FY26 Q4: -1.4% Operating margin (TTM), FY27 Q1: 0.7% Operating margin (TTM), FY27 Q2: 2.5% 2.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q3 -43.4%
FY24 Q4 -38.3%
FY25 Q1 -31.6%
FY25 Q2 -25.2%
FY25 Q3 -19.8%
FY25 Q4 -13.8%
FY26 Q1 -9.7%
FY26 Q2 -5.8%
FY26 Q3 -1.9%
FY26 Q4 -1.4%
FY27 Q1 0.7%
FY27 Q2 2.5%
FCF margin (TTM) Phreesia, Inc.
-20% -10% 0% 10% 20% FY24 Q3 FY25 Q2 FY26 Q1 FY27 Q2 FCF margin (TTM), FY24 Q3: -14.6% FCF margin (TTM), FY24 Q4: -10.7% FCF margin (TTM), FY25 Q1: -6.6% FCF margin (TTM), FY25 Q2: -2.1% FCF margin (TTM), FY25 Q3: 1.2% FCF margin (TTM), FY25 Q4: 5.6% FCF margin (TTM), FY26 Q1: 8.4% FCF margin (TTM), FY26 Q2: 9.6% FCF margin (TTM), FY26 Q3: 10.8% FCF margin (TTM), FY26 Q4: 14.1% FCF margin (TTM), FY27 Q1: 15.3% FCF margin (TTM), FY27 Q2: 15.9% 15.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q3 -14.6%
FY24 Q4 -10.7%
FY25 Q1 -6.6%
FY25 Q2 -2.1%
FY25 Q3 1.2%
FY25 Q4 5.6%
FY26 Q1 8.4%
FY26 Q2 9.6%
FY26 Q3 10.8%
FY26 Q4 14.1%
FY27 Q1 15.3%
FY27 Q2 15.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2018 Jan 2018 2019 Jan 2019 2020 Jan 2020 2021 Jan 2021 2022 Jan 2022 2023 Jan 2023 2024 Jan 2024 2025 Jan 2025 2026 Jan 2026 LTM Jul 2026
Income
Revenue 80 100 125 149 213 281 356 420 481 508
EBITDA −5 2 −1 −10 −96 −151 −107 −30 25 50
Operating income −15 −9 −15 −26 −117 −177 −136 −58 −7 13
Net income −18 −15 −20 −27 −118 −176 −137 −59 2 10
Diluted EPS −$12.40 −$12.27 −$2.25 −$0.69 −$2.37 −$3.36 −$2.51 −$1.02 $0.04 $0.17
Growth (year on year)
Revenue — +25.1% +24.9% +19.1% +43.4% +31.7% +26.8% +17.8% +14.5% +12.9%
EBITDA — — −165.4% — — — — — — —
Margins
EBITDA margin −6.2% 2.1% −1.1% −6.6% −44.8% −53.8% −30.0% −7.2% 5.2% 9.8%
Operating margin −18.2% −9.5% −12.3% −17.3% −54.8% −62.9% −38.3% −13.8% −1.4% 2.5%
Net margin −22.8% −15.1% −16.3% −18.4% −55.4% −62.7% −38.4% −13.9% 0.5% 2.1%
Free-cash-flow margin −22.2% −6.9% −5.0% −5.6% −43.7% −33.8% −10.7% 5.6% 14.1% 15.9%
Cash flow
Cash from operations −11 −2 1 3 −75 −90 −32 32 79 91
Capital spending 7 5 7 11 18 5 6 9 11 11
Free cash flow −18 −7 −6 −8 −93 −95 −38 24 68 81
Stock-based pay 1 1 6 13 36 59 72 67 67 59
Free cash flow after stock pay −19 −8 −12 −22 −129 −154 −110 −43 0 21
Balance sheet
Cash 11 2 90 219 314 177 88 84 74 75
Total debt 0 — — — — — — — — 127
Net debt (negative = net cash) −11 −2 −90 −219 −314 −177 −88 −84 −74 53
Diluted shares 3m 4m 41m 40m 50m 52m 55m 58m 61m 62m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

6 of 7 checks passed · July 31, 2026
What it owns · $647m
Short-term assets $254mLonger-term assets $393m
What it owes, and who funded it · $647m
Short-term liabilities $144mLonger-term liabilities $131mShareholders' equity $372m
  • Short-term assets cover short-term liabilities $254m of assets due within a year against $144m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $254m short-term assets against $131m of longer-dated liabilities.
  • More cash than debt $75m of cash against $1m of debt.
  • Debt below 40% of shareholders' equity Debt is 0% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 0% over five years.
  • A year's operating cash flow covers at least 20% of debt $91m of operating cash flow against $1m of debt.
  • Operating profit covers interest at least five times over Operating income of $13m against $10m of interest.

From Phreesia, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+5.5%
year over year
R&D spending
22.9%
of revenue
Days sales outstanding
64 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care technology
Last 12 months unless stated PHR WGS DOCS GDRX HSTM HCAT Median
Revenue, last 12 months $508m $454m $656m $785m $321m $292m $292m
Revenue growth, last 12 months 12.9% 25.4% 11.2% −1.8% 8.8% −7.5% 8.8%
Revenue growth, 3-year average 16.7% 24.3% 14.5% 1.8% 5.4% 0.9% 0.8%
Revenue growth, latest quarter 10.4% 11.4% 7.3% −1.3% 12.5% −12.7% 7.4%
Gross margin — 69.4% 88.1% — 59.1% — 58.6%
Operating margin 2.5% −20.3% 29.6% 9.5% 8.0% −84.4% −12.5%
Operating margin, 3-year average −9.5% −19.0% 35.4% 5.6% 7.3% −48.1% −18.8%
Net margin 2.1% −23.4% 25.5% 2.1% 6.6% −90.6% −12.5%
Cash from operations / revenue 18.0% −10.7% 46.7% 25.7% 22.4% 9.7% 9.7%
Free-cash-flow margin 15.9% −16.7% 46.7% 25.1% 21.7% 9.2% 9.2%
Free-cash-flow margin, 3-year average 7.8% −18.7% 43.6% 21.7% 21.4% 1.7% 8.2%
Stock pay / revenue 11.7% 7.9% 20.8% 9.7% 2.7% 6.0% 9.5%
Change in share count 5.5% 2.6% −2.5% −9.8% −3.3% 10.3% 2.9%

Median of all 23 companies we cover in health care technology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

23 health care technology companies
Measure Company Peer median Rank
Revenue growth Growth 12.9% 8.8% 10 of 23
Change in growth rate Growth -1.1pp -0.3pp 16 of 23
Operating margin Profitability 2.5% -6.6% 10 of 22
Net margin Profitability 2.1% -12.5% 10 of 23
Free-cash-flow margin Cash generation 15.9% 10.6% 8 of 22
Stock pay as % of revenue Cash generation 11.7% 9.7% 14 of 22
Long-term debt as % of assets Balance sheet 0.2% 20.1% 2 of 15
Change in share count Balance sheet 5.5% 2.6% 12 of 19
Days sales outstanding Balance sheet 64 days 58 days 12 of 21

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to January 31, 2026
Products and services
Line of business Revenue Share YoY
Subscription and Services $219M 45.7% ▲ 11.7%
Network Solutions $140M 29.1% ▲ 14.9%
Payment Solutions $121M 25.3% ▲ 19.4%

From Phreesia, Inc.'s 10-K filed March 31, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$600M
Institutions reporting
225
Shares held vs prior quarter
▼ 0.7%
Positions opened / closed
36 / 54

Top buyers and sellers, Q2 2026: 130 institutions bought and 113 sold ; the biggest buyer was AQR Capital Management LLC (+1.3M shares) and the biggest seller Prosight Management, LP (−1.1M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Pale Fire Capital Se $91.8M 8.9M 15.3% ▲ 3.2%
Blackrock, Inc. $72.2M 7.0M 12.0% ▲ 18.6%
AQR Capital Management LLC $32.4M 3.2M 5.4% ▲ 70.1%
Vanguard Portfolio Management LLC $30.7M 3.0M 5.1% ▼ 10.4%
Vanguard Capital Management LLC $26.2M 2.5M 4.4% ▲ 2.8%
Acadian Asset Management LLC $16.5M 1.6M 2.8% ▲ 56.1%
State Street Corp $16.2M 1.6M 2.7% ▲ 7.0%
Goldman Sachs Group Inc $14.8M 1.4M 2.5% ▲ 39.2%
Geode Capital Management, LLC $13.5M 1.3M 2.3% ▼ 4.4%
T. Rowe Price Investment Management, Inc. $13.3M 1.3M 2.2% New
Algert Global LLC $12.4M 1.2M 2.1% ▼ 12.7%
Jacobs Levy Equity Management, Inc $11.5M 1.1M 1.9% ▲ 3.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Phreesia, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $28.8M 8 trades by 3 insiders, last 12 months Insider sales History → $2M 37 trades by 8 insiders · 29% under pre-set plans
Net ▲ $26.8M net buying
Insider Date Trade Shares Price Value
Linetsky David President, Network Solutions October 22, 2026 Buy 35 $10.35 $362
Linetsky David President, Network Solutions October 22, 2026 Buy 35 $9.15 $320
Hoffman Allison C General Counsel & Secretary September 21, 2026 Sell pre-set plan 6,662 $10.08 $67,153
Hui Yvonne Principal Accounting Officer July 16, 2026 Sell pre-set plan 1,247 $10.92 $13,617
Egbuonu-Davis Lisa Director July 14, 2026 Sell pre-set plan 536 $10.70 $5,735
Hui Yvonne Principal Accounting Officer July 6, 2026 Sell pre-set plan 1,371 $10.84 $14,862
Egbuonu-Davis Lisa Director June 25, 2026 Sell pre-set plan 2,546 $9.53 $24,263
Hui Yvonne Principal Accounting Officer May 18, 2026 Sell pre-set plan 431 $8.85 $3,814
Hoffman Allison C General Counsel & Secretary April 20, 2026 Sell pre-set plan 6,176 $9.06 $55,955
Hui Yvonne Principal Accounting Officer April 17, 2026 Sell pre-set plan 1,327 $9.28 $12,315
Hui Yvonne Principal Accounting Officer April 16, 2026 Sell pre-set plan 10,063 $9.08 $91,372
Linetsky David President, Network Solutions April 10, 2026 Sell pre-set plan 8,332 $8.07 $67,239

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 14 trades and filings

In the last 12 months, 2 members of Congress disclosed 0 purchases and 3 sales of Phreesia, Inc. shares.

  • Gilbert Ray Cisneros, Jr.(D-CA 31):Sale (full), $1,001 - $15,000, traded August 26, 2026, filed September 10, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Sale (partial), $1,001 - $15,000, traded August 25, 2026, filed September 10, 2026
  • Josh Gottheimer(D-NJ 5):Sale (full), $1,001 - $15,000, traded March 5, 2026, filed April 8, 2026

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around December 7, 2026 estimated from the company's past filing pattern, not announced

  • September 2, 2026
  • May 27, 2026
  • April 3, 2026
  • March 30, 2026
  • December 8, 2025
  • September 4, 2025

Recent SEC filings

Data status

When each part of this page on Phreesia, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Phreesia, Inc. in brief

What does Phreesia, Inc. do?
Phreesia, Inc. is a US-listed company in the health care technology industry. Its financial year ends in January.
What is Phreesia, Inc.'s stock ticker?
Phreesia, Inc. trades under the ticker PHR on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Phreesia, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Phreesia, Inc. reported revenue of $508M, 12.9% higher than a year earlier, according to its SEC filings.
What is Phreesia, Inc.'s free cash flow?
Phreesia, Inc.'s free-cash-flow margin is 15.9% of revenue over the trailing twelve months, ranking 8 of the 22 health care technology companies we cover.
Who are Phreesia, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Pale Fire Capital Se, Blackrock, Inc. and AQR Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Phreesia, Inc.'s market cap?
On November 2, 2026, Phreesia, Inc.'s market capitalisation was about $777M, with a price-to-earnings ratio of 74.4 and net debt of $52.5M. Market figures come from third-party market data and may be delayed.
How much debt does Phreesia, Inc. have?
Phreesia, Inc.'s debt-to-equity ratio is 0.3%, from its latest balance sheet (0.1% five years earlier). The financial health section below sets out its other solvency checks.
Who are Phreesia, Inc.'s competitors?
In our Health Care Technology peer group, the companies closest to Phreesia, Inc. are Genedx Holdings Corp., Doximity, Inc., Goodrx Holdings, Inc., Healthstream Inc and Health Catalyst, Inc. The side-by-side comparison below sets their revenue, margins and growth against Phreesia, Inc.'s.
Are insiders buying or selling Phreesia, Inc. stock?
Over the last 12 months, Phreesia, Inc.'s directors and officers reported 8 open-market purchases and 37 sales on Form 4. The insider trading page charts every trade.
When is Phreesia, Inc.'s next earnings date?
Around December 7, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Phreesia, Inc. announces its own schedule.